Research Analysts Offer Predictions for VTVT Q3 Earnings

vTv Therapeutics Inc. (NASDAQ:VTVT) – HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for shares of vTv Therapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will post earnings per share of ($1.01) for the quarter, down from their previous forecast of ($0.54). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for vTv Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for vTv Therapeutics’ Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($4.60) EPS, FY2028 earnings at ($4.40) EPS, FY2029 earnings at ($3.78) EPS and FY2030 earnings at ($3.61) EPS.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.08).

A number of other brokerages have also recently issued reports on VTVT. Weiss Ratings upgraded vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. BTIG Research raised their target price on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Zacks Research downgraded shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Wall Street Zen lowered shares of vTv Therapeutics from a “buy” rating to a “sell” rating in a research report on Saturday. Finally, Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target for the company. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Stock Down 3.1%

VTVT stock opened at $34.29 on Monday. The business has a 50 day moving average price of $33.40 and a two-hundred day moving average price of $34.81. The company has a market cap of $135.10 million, a price-to-earnings ratio of -32.35 and a beta of 0.29. vTv Therapeutics has a twelve month low of $14.00 and a twelve month high of $44.00.

Institutional Investors Weigh In On vTv Therapeutics

Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics during the fourth quarter worth $221,000. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics in the fourth quarter valued at $731,000. Finally, Geode Capital Management LLC raised its position in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the period. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.